| Cash Flow | 2025-09-30 | 2025-06-30 | 2025-03-31 |
|---|---|---|---|
| Net loss | -6,862,468 | -6,572,723 | -3,959,440 |
| Goodwill impairment charges | 0 | - | - |
| Shares issued as part of stock grants to vendors | 0 | - | - |
| Loss on issuance of financial instruments | -443,020 | -138,020 | - |
| Original issue discount and interest accrued on quantum convertible note-Quantum Notes | - | 0 | - |
| Original issue discount and interest accrued on quantum convertible note | 0 | - | - |
| Change in fair value of financial instruments | 1,412,351 | -1,416,296 | -1,399,491 |
| Loss on extinguishment of loan | -126,125 | -126,125 | - |
| Deferred income tax assets and liabilities | 0 | 0 | - |
| Amortization of discount on note payable | 0 | 0 | 0 |
| Allowance for expected credit losses | 521,098 | 246,884 | 120,919 |
| Depreciation and amortization | 1,941,654 | 1,294,636 | 647,037 |
| Stock-based compensation | 764,036 | 764,036 | 392,106 |
| Amortization of right-of-use assets | 63,906 | 41,815 | 20,524 |
| Accounts receivable | 1,383,218 | 147,264 | 255,130 |
| Due from related party | -247,042 | -290,534 | -242,500 |
| Prepaids and other current assets | -64,304 | -36,787 | 83,168 |
| Accounts payable and accrued liabilities | 3,357,851 | 951,797 | 692,586 |
| Deferred revenue | 662,279 | 682,287 | 358,860 |
| Due to related parties | 0 | 0 | 0 |
| Operating lease liabilities | -52,910 | -34,324 | -16,778 |
| Right-of-use liabilities | - | 0 | - |
| Income tax payable | 0 | - | - |
| Net cash used in operating activities | -1,519,632 | -765,094 | -440,493 |
| Cash acquired from business combination- idoc | 0 | 0 | - |
| Purchases of fixed assets | 22,776 | 15,466 | 11,873 |
| Net cash used in investing activities | -22,776 | -15,466 | -11,873 |
| Proceeds from convertible note-Quantum Convertible Note | 0 | - | - |
| Proceeds from quantum convertible note | - | 0 | 509,366 |
| Proceeds from convertible note-September2024Convertible Note | 0 | - | - |
| Proceeds from reverse recapitalization with dhac | 0 | 0 | - |
| Repayment on advances of related party | 0 | 0 | - |
| Repayment on extension note | 0 | - | - |
| Repayment on additional bridge financing | 0 | - | - |
| Repayment on encompass purchase liability | 0 | 44 | - |
| Repayment on note payable | 668,092 | 0 | - |
| Payment to shareholder | 10,000 | 10,000 | 10,000 |
| Proceeds from issuance of common stock | 541,184 | 90,634 | 90,634 |
| Proceeds from notes issued during the period | 1,907,791 | 726,237 | - |
| Payments on factoring payable | 56,787 | 35,787 | 28,627 |
| Payments due on acquisition purchase | 44 | - | - |
| Payments on finance lease liability | - | -25,000 | 25,000 |
| Payments on financing lease liability | 25,000 | - | - |
| Net cash provided by financing activities | 1,689,052 | 746,040 | 536,373 |
| Net change in cash | 146,644 | -34,520 | 84,007 |
| Cash and cash equivalents at beginning of period | 326,115 | 326,115 | 326,115 |
| Cash and cash equivalents at end of period | 472,759 | 291,595 | 410,122 |
VSEE HEALTH, INC. (VSEE)
VSEE HEALTH, INC. (VSEE)